前列腺癌磁共振引导放射治疗后的患者报告结局:系统综述与荟萃分析
该系统综述纳入11项观察性研究和1项随机对照试验(n=897),评估磁共振引导放射治疗(MRgRT)对前列腺癌患者报告结局的影响。荟萃分析显示,泌尿和肠道症状在放疗结束至1个月随访期间出现短暂加重,3个月后恢复;一般生活质量领域无临床相关变化。
要点
- MRgRT后泌尿和肠道症状在放疗结束至1个月随访期间短暂加重,3个月后恢复。
- EPIC-26泌尿领域MD为-10.0(95%CI -12.0至-8.1,I²=0%),EORTC QLQ-PR25泌尿领域MD为8.6(95%CI -4.7至22.0,I²=97%)。
- EORTC QLQ C30一般生活质量领域未发现临床相关变化。
核心结论
- 前列腺癌MRgRT导致患者报告的泌尿和肠道症状在治疗后第一个月内较放疗前短暂加重,3个月时恢复。
- 一般生活质量领域未发现临床相关变化。
- 这些结果为患者咨询提供了重要信息,并可作为未来研究的基准。
研究设计与样本
- 系统综述与荟萃分析,检索PubMed、EMBASE和Cochrane Library(2023年10月),采用PICOS框架确定纳入标准。
- 纳入评估前列腺癌MRgRT后患者报告结局、样本量>10的研究,共11项观察性研究和1项随机对照试验(n=897)。
- 9项研究为初治前列腺癌以MRgRT作为一线治疗(n=813),3项为MRgRT作为二线治疗(n=84)。
- 使用Cochrane非随机干预研究偏倚风险工具和Cochrane随机试验偏倚风险工具评估方法学质量,5项研究存在显著偏倚风险。
- 采用随机效应模型进行荟萃分析,使用I²统计量评估研究间异质性。
主要发现
- EORTC QLQ C30和EORTC QLQ-PR25评分从3项研究中合并,EPIC-26评分从4项研究中合并。
- 泌尿领域:EPIC-26在放疗结束至1个月随访时MD为-10.0(95%CI -12.0至-8.1,I²=0%);EORTC QLQ-PR25同期MD为8.6(95%CI -4.7至22.0,I²=97%)。
- 肠道领域:EPIC-26在放疗结束或1个月随访时MD为-4.7(95%CI -9.2至-0.2,I²=82%);EORTC QLQ-PR25未发现相关MD。
- 两个领域在3个月随访后均未发现相关MD;EORTC QLQ C30一般生活质量领域未发现相关MD。
关键数值与推荐
- 纳入标准:评估前列腺癌MRgRT后患者报告结局、样本量>10的研究。
- 采用最小重要差异(MID)解释与放疗前比较的平均差异(MD)。
临床怎么用
- 这些结果可为前列腺癌MRgRT的患者咨询提供信息,并作为未来研究的基准。
局限性
- 5项研究存在显著偏倚风险。
- EORTC QLQ-PR25泌尿领域合并分析异质性I²=97%。
- EPIC-26肠道领域合并分析异质性I²=82%。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This systematic review provides an overview of literature on the impact of magnetic resonance-guided radiation therapy (MRgRT) on patient-reported outcomes (PROs) in patients with prostate cancer (PC). METHODS AND MATERIALS: A systematic search was performed in October 2023 in PubMed, EMBASE, and Cochrane Library. The Patient, Intervention, Comparison, Outcomes, and Study design (PICOS) framework was used to determine eligibility criteria. Included were studies assessing PROs following MRgRT for PC with a sample size >10. Methodological quality was assessed using the Cochrane's Risk of Bias in Nonrandomized Studies - of Interventions and Cochrane's risk of bias tool for randomized trials. Relevant mean differences (MDs) compared with pre-RT were interpreted using minimal important differences. Meta-analyses were performed using random-effects models. Between-study heterogeneity was assessed using the I2 statistic. RESULTS: Eleven observational studies and 1 randomized controlled trial (n = 897) were included. Nine studies included patients with primary PC with MRgRT as first-line treatment (n = 813) and 3 with MRgRT as second-line treatment (n = 84). Substantial risk of bias was found in 5 studies. European Organization for Research and Treatment Quality of Life Questionnaire (EORTC QLQ) core 30 (C30) and EORTC QLQ prostate cancer module (PR25) scores were pooled from 3 studies, and Expanded Prostate Cancer Index Composite (EPIC)-26 scores were pooled from 4 studies. Relevant MDs for the urinary domain were found with the EPIC-26 (MD, -10.0; 95% CI, -12.0 to -8.1; I2 = 0%) and the EORTC QLQ-PR25 (MD, 8.6; 95% CI, -4.7 to 22.0; I2 = 97%), both at end-RT to 1-month follow-up. Relevant MDs for the bowel domain were found with the EPIC-26 (MD, -4.7; 95% CI, -9.2 to -0.2; I2 = 82%) at end-RT or 1-month follow-up, but not with the EORTC QLQ-PR25. For both domains, no relevant MDs were found after 3 months of follow-up. No relevant MDs were found in the general quality of life domains of the EORTC QLQ C30. CONCLUSIONS: MRgRT for PC results in a temporary worsening of patient-reported urinary and bowel symptoms during the first month after treatment compared with pre-RT, resolving at 3 months. No clinically relevant changes were found for general quality of life domains. These results provide important information for patient counseling and can serve as a benchmark for future studies.
引用
- Westerhoff JM, Lalmahomed TA, Meijers LTC, et al. Patient-Reported Outcomes Following Magnetic Resonance-Guided Radiation Therapy for Prostate Cancer: A Systematic Review and Meta-Analysis. Int J Radiat Oncol Biol Phys. 2024. PMID: 38838994. doi:10.1016/j.ijrobp.2024.05.028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。